Selective TBK1/IKKi dual inhibitors with anticancer potency. - Wikidata - wikimedia - TriplyDB

Selective TBK1/IKKi dual inhibitors with anticancer potency.

Selective TBK1/IKKi dual inhibitors with anticancer potency.

http://www.wikidata.org/entity/Q37626577

about

Identification of Novel Inhibitors of the Type I Interferon Induction Pathway Using Cell-Based High-Throughput Screening Detection of IKKε by immunohistochemistry in primary breast cancer: association with EGFR expression and absence of lymph node metastasis.Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation.TBK1 inhibitors: a review of patent literature (2011 - 2014).Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression.Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications Roles for the IKK-Related Kinases TBK1 and IKKε in Cancer

P2860

Q27469008-89EFE5DA-3102-4D23-BA21-6AB0CCF65F81 Q33717414-B4FD9572-734B-42F0-B82D-17BD370E1684 Q35624305-0FFBC063-73D4-41F7-A087-0888B52E2D5F Q36507879-09E76C61-915A-44AB-910D-766B57AD8E6D Q38570615-B0FCFAF4-4A72-4CFC-9921-00BF6F847DDE Q38879970-1981B82F-656A-4D97-A3A5-0DF2BACCD5FE Q42314708-CAE000FE-1BA3-44D7-ACC6-F9528453074E Q57107409-466C1FE9-953E-4914-9F8A-3BB605E66F12 Q58737053-1691560B-B25E-401F-9378-2DF2B2ED317C

P2860

Selective TBK1/IKKi dual inhibitors with anticancer potency.

http://www.wikidata.org/entity/Q37626577

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Selective TBK1/IKKi dual inhibitors with anticancer potency.

@en

Selective TBK1/IKKi dual inhibitors with anticancer potency.

@nl

type

label

Selective TBK1/IKKi dual inhibitors with anticancer potency.

@en

Selective TBK1/IKKi dual inhibitors with anticancer potency.

@nl

prefLabel

Selective TBK1/IKKi dual inhibitors with anticancer potency.

@en

Selective TBK1/IKKi dual inhibitors with anticancer potency.

@nl

P1433

Q37626577-3CE12DBB-17BF-4B54-93DF-40A798163B35

P1476

Q37626577-4B10A907-079B-4C39-BC4B-B58405AFCD1B

P2093

Q37626577-04580006-3DE6-4476-BF9A-D6A035381EB8

Q37626577-3166635C-862A-4575-B434-BD1167C38C5D

Q37626577-645E1235-0DBF-437F-B882-E06A80A7FAC2

Q37626577-6DD069AF-3E27-4776-9DB6-6DF8DE01CE58

Q37626577-87CCB3DF-0887-4335-A432-97BBFC9D0FA0

Q37626577-B20C209E-FE2E-4939-8334-FDC443C3EC24

Q37626577-CFC3E801-8125-4A9D-AC12-7E57590F242F

Q37626577-D4A8E6BA-1B9E-4126-AA90-2F74965E4027

Q37626577-E0A6ECD3-E266-4D5C-9130-6646C168A627

Q37626577-F6F523FF-DDC7-42E3-A7AE-8BB4BD40E257

P2860

Q37626577-039EE7E2-573A-4CF6-9A2D-BFC649A58653

Q37626577-0ADAF76C-331C-4815-BF21-DDB88DAC167B

Q37626577-0BEAFBFC-B776-475C-A01D-4B24480C953C

Q37626577-150BED2E-9A39-494A-97EE-7F045B47E846

Q37626577-17750453-06B4-48C2-9999-E2FBD34B4347

Q37626577-32B755F3-1700-4F54-99AC-08C43E194C93

Q37626577-38C5751F-C5B8-4EDE-A750-430FC73E74B2

Q37626577-38C74B1D-7B95-4D1C-B3C5-19EFB11989E5

Q37626577-39AD4C3E-03B0-467E-96DB-21BF96233E0E

Q37626577-3F84098E-CF72-4BFE-A878-E0D04BFFCD42

P304

Q37626577-439DEBC4-C6EC-40C4-8A2F-FA52D20753FE

P31

Q37626577-5F240BA4-16F6-4A4F-89F7-7BF508BA773D

P356

Q37626577-37564AB2-EA9F-40E1-982D-E62003D8F188

P433

Q37626577-F3198419-35C3-4360-94FE-52ABE2BEBD6A

P478

Q37626577-C0E239D9-F0B2-451E-A78A-6E5CC74EA18C

P577

Q37626577-4A678DD3-FCEF-4C24-A887-6D36C9310ACD

P5875

Q37626577-23517B8D-609F-497F-8611-14E9B1C0AE7E

P698

Q37626577-53BB5B91-346D-4E45-9254-8A15F1855673

P932

Q37626577-D19401FC-3A7A-40BA-B391-67B9D4B09A2E

P356

P1433

International Journal of Cancer

P1476

Selective TBK1/IKKi dual inhibitors with anticancer potency.

@en

P2093

Ji-Hak Jeong

http://www.w3.org/2001/XMLSchema#string

Jieying Peng

http://www.w3.org/2001/XMLSchema#string

Jijia Li

http://www.w3.org/2001/XMLSchema#string

Jingjia Huang

http://www.w3.org/2001/XMLSchema#string

Jun-Li Luo

http://www.w3.org/2001/XMLSchema#string

Rui Wei

http://www.w3.org/2001/XMLSchema#string

Sun-Jin Park

http://www.w3.org/2001/XMLSchema#string

Yangbo Feng

http://www.w3.org/2001/XMLSchema#string

Yen Ting Chen

http://www.w3.org/2001/XMLSchema#string

Zhiyong Luo

http://www.w3.org/2001/XMLSchema#string

P2860

Emerging roles for the non-canonical IKKs in cancer

Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase

Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription

Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo

Identification of NAP1, a regulatory subunit of IkappaB kinase-related kinases that potentiates NF-kappaB signaling

Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity

NF-kappaB: linking inflammation and immunity to cancer development and progression

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

P304

1972-1980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.28507

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258036825

http://www.w3.org/2001/XMLSchema#string

P698

24150799

http://www.w3.org/2001/XMLSchema#string

P932

3947486

http://www.w3.org/2001/XMLSchema#string